4.7 Article

Modeling disease progression via multi-task learning

期刊

NEUROIMAGE
卷 78, 期 -, 页码 233-248

出版社

ACADEMIC PRESS INC ELSEVIER SCIENCE
DOI: 10.1016/j.neuroimage.2013.03.073

关键词

Alzheimer's disease; Disease progression; Multi-task learning; Fused Lasso; MMSE; ADAS-Cog

资金

  1. Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health) [U01 AG024904]
  2. National Institute on Aging
  3. National Institute of Biomedical Imaging and Bioengineering
  4. Abbott
  5. Alzheimer's Association
  6. Alzheimer's Drug Discovery Foundation
  7. Amorfix Life Sciences Ltd.
  8. AstraZeneca
  9. Bayer HealthCare
  10. BioClinica, Inc.
  11. Biogen Idec Inc.
  12. Bristol-Myers Squibb Company
  13. Eisai Inc.
  14. Elan Pharmaceuticals Inc.
  15. Eli Lilly and Company
  16. F. Hoffmann-La Roche Ltd.
  17. Genentech, Inc.
  18. GE Healthcare
  19. Innogenetics, N.V.
  20. Janssen Alzheimer Immunotherapy Research & Development, LLC.
  21. Johnson & Johnson Pharmaceutical Research & Development LLC.
  22. Medpace, Inc.
  23. Merck Co., Inc.
  24. Meso Scale Diagnostics, LLC.
  25. Novartis Pharmaceuticals Corporation
  26. Pfizer Inc.
  27. Servier
  28. Synarc Inc.
  29. Takeda Pharmaceutical Company
  30. Canadian Institutes of Health Research
  31. NIH [P30 AG010129, K01 AG030514]
  32. Dana Foundation
  33. US National Science Foundation (NSF) [IIS-0812551, IIS-0953662, MCB-1026710, CCF-1025177]
  34. National Library of Medicine [R01 LM010730]

向作者/读者索取更多资源

Alzheimer's disease (AD), the most common type of dementia, is a severe neurodegenerative disorder. Identifying biomarkers that can track the progress of the disease has recently received increasing attentions in AD research. An accurate prediction of disease progression would facilitate optimal decision-making for clinicians and patients. A definitive diagnosis of AD requires autopsy confirmation, thus many clinical/cognitive measures including Mini Mental State Examination (MMSE) and Alzheimer's Disease Assessment Scale cognitive subscale (ADAS-Cog) have been designed to evaluate the cognitive status of the patients and used as important criteria for clinical diagnosis of probable AD. In this paper, we consider the problem of predicting disease progression measured by the cognitive scores and selecting biomarkers predictive of the progression. Specifically, we formulate the prediction problem as a multi-task regression problem by considering the prediction at each time point as a task and propose two novel multi-task learning formulations. We have performed extensive experiments using data from the Alzheimer's Disease Neuroimaging Initiative (ADNI). Specifically, we use the baseline MRI features to predict MMSE/ADAS-Cog scores in the next 4 years. Results demonstrate the effectiveness of the proposed multi-task learning formulations for disease progression in comparison with single-task learning algorithms including ridge regression and Lasso. We also perform longitudinal stability selection to identify and analyze the temporal patterns of biomarkers in disease progression. We observe that cortical thickness average of left middle temporal, cortical thickness average of left and right Entorhinal, and white matter volume of left Hippocampus play significant roles in predicting ADAS-Cog at all time points. We also observe that several MRI biomarkers provide significant information for predicting MMSE scores for the first 2 years, however very few are shown to be significant in predicting MMSE score at later stages. The lack of predictable MRI biomarkers in later stages may contribute to the lower prediction performance of MMSE than that of ADAS-Cog in our study and other related studies. (C) 2013 Elsevier Inc. All rights reserved.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据